Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT
Anti-CD19 Donor-derived CAR-T Cells for Patients With Relapsed B Cell Malignancies After Hematopoietic Stem Cell Transplantation: a Multi-center, Uncontrolled Trial.
Sponsor: 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
This PHASE1 trial investigates B Cell Leukemia and Relapsed Adult ALL and is currently ongoing. 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Jan 2023 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Oct 2021 — Jan 2023 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE1
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Dec 2020 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Chongqing University Cancer Hospital
- First Affiliated Hospital of Zhejiang University
- Gracell Biotechnologies (Shanghai) Co., Ltd.
- Tang-Du Hospital
- The Affiliated Hospital Of Guizhou Medical University
- The First Affiliated Hospital of Anhui Medical University
- The General Hospital of Western Theater Command
- The Second Affiliated Hospital of Chongqing Medical University
- Xinqiao Hospital of Chongqing
For direct contact, visit the study record on ClinicalTrials.gov .